Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
-
Targeted radiation shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a radioactive drug (177Lu-PSMA) in people with advanced or spreading cancers that have a specific marker (PSMA) seen on PET scans. The treatment aims to control the disease by delivering radiation directly to cancer cells. About 83 participants will receive up to…
Phase: PHASE2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 17, 2026 03:32 UTC
-
5-Day radiation blast targets mesothelioma after surgery
Disease control OngoingThis study tests a new way to give radiation therapy to people with malignant pleural mesothelioma, a rare and serious lung cancer. The treatment is given over just 5 days using a special machine called Tomotherapy. The goal is to see if this short, intense radiation is safe and …
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 13, 2026 16:00 UTC